Figure 6.

Metformin suppresses the effect of CD19-CAR T-cell cytotoxicity in vivo. (A) The schematic diagram of the progression of experiment in vivo. (B) Bioluminescence imaging data from Raji-ffluc bearing NSG mice (N=5) that had received 1×10⁶ CD19-CAR T cells and drug treatment. NSG mice (N=5) that received drinking water were used as control. Mice were monitored for 18 days via luminescence imaging to follow tumor progression. (C) Survival curve of mice receiving metformin or no drug treatment. P-values were calculated by log-rank test analysis. *P<0.05, versus the control group. Results represent one independent trial.

Abbreviations: CAR, chimeric antigen receptor; d, days; min, minimum; max, maximum.